Receive a FREE Mesothelioma Treatment
Information Packet

Mesothelioma

ALIMTA Plus Gemcitabine as Front-Line Chemotherapy

 

ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients with Malignant Pleural or Peritoneal Mesothelioma. A phase II Clinical Trial
Purpose:

ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients with Malignant Pleural or Peritoneal Mesothelioma. A phase II Clinical Trial.

Patient Inclusion:

Histologically proven diagnosis of Malignant Pleural or Peritoneal Mesothelioma
2 Weeks post pleurodesis
Radiotherapy MUST BE completed at least 4 weeks
Patient MUST have measurable disease
At least 4 weeks must have elapsed and patients must have recovered from all side effects of Surgery

Exclusion Criteria:

You are excluded from this trial if you have received prior chemotherapy for mesothelioma
You are excluded from this trial if you have brain metastases.
You are excluded from this trial if you have active infection
You are excluded from this trial if you have pregnant or breast feeding.
You are excluded from this trial if you have inability to take folic acid or vitamin B12 administration

Location/Contact Information:
Mary Hesdorffer, RN, BSN, Clinical Research Nurse
Columbia-Presbyterian Medical Center
Herbert Irving Comprehensive Cancer Center
Columbia University
161 Fort Washington Ave.
New York, NY 10032
Telephone: 212-305-1252
Fax: 212-305-6891
Email: mp317@columbia.edu